A review of chemical agents in the pharmacotherapy of addiction

Current Medicinal Chemistry

Volumn 9, Issue 20, 2002, Pages 1807-1818

  Levi, M S ^a   Borne, R F ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Acamprosate Addiction BP 897 Cocaine GBR12909 Iboga Lofexidine Memantine

Indexed keywords

18 METHOXYCORONARIDINE; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; ACAMPROSATE; ALCOHOL; ALKALOID; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; AMINO ACID RECEPTOR BLOCKING AGENT; BP 897; BRITLOFEX; CENTRAL STIMULANT AGENT; CLONIDINE; COCAINE; DIZOCILPINE; IBOGAINE; IBOGAMINE; LOFEXIDINE; MEMANTINE; METHAMPHETAMINE; MONOCLONAL ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALTREXONE; NICOTINE; NIFEDIPINE; NIH 101567; NORIBOGAINE; OPIATE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TABERNANTHINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANOXERINE;

ALCOHOLISM; COCAINE DEPENDENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG APPROVAL; DRUG COMPETITION; DRUG DEPENDENCE; DRUG DESIGN; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HALLUCINATION; HUMAN; HYPOTENSION; NEUROTOXICITY; NONHUMAN; OPIATE ADDICTION; RAT; REVIEW; STRUCTURE ACTIVITY RELATION; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; UNITED STATES;

EID: 0036385125     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/0929867023368980     Document Type: Review

References (125)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. American Psychiatric Association: Washington, 1994.
2. Lindesmith, A.R. Addiction and Opiates, Aldine: Chicago, 1968.
3. Lindesmith, A.R. The Addict and the Law, Indiana Univ.: Bloomington, 1965.
4. United States Dept. of State, International Information Programs, Drug Facts and Figures. http://usinfo.state.gov/products/pubs/archive/drugfact s/
5. Wise, R.A. Curr. Opinion. Neurobiol., 1996, 22, 362.
6. Kalivas, P.W.; Stewart, J. Brain Res. Rev., 1991, 16, 223.
7. Strakowski, S.M.; Sax, K.W. Biol. Psychol., 1998, 44, 1171.
8. Robinson, T.E.; Berridge, K.C. Brain. Res. Rev., 1993, 18, 247.
9. Wolf, M.E. Prog. Neurobiol., 1998, 54, 679.
10. Breiter, H.C.; Gollub, R.L.; Weisskoff, R.M.; Kennedy, D.N.; Makris, N.; Berke, J.D.; Goodman, J.M.; Kantor, H.L.; Gastfriend, D.R.; Riorden, J.P.; Mathew, R.T.; Rosen, B.R.; Hyman, S.E. Neuron, 1997, 19, 591.
11. Childress, A.R.; Mozley, P.D.; McElgin, W.; Fitzgerald, J.; Reivich, M.; O'Brien, C.P. Am. J. Psychiatry, 1999, 156, 11.
12. Vorel, S.R.; Liu, X.; Hayes, R.J.; Spector, J.A.; Gardner, E.L. Science, 2001, 292, 1175.
13. As quoted in: Holden, C. Science, 2001, 292, 1039.
14. http://www.drugabuse.gov/infofax/treatmed.html.
15. Carroll, F.I.; Howell, L.L.; Kuhar, M.J. J. Med Chem., 1999, 42, 2721.
16. Aubry-Lecomte. Archives de Médicine navale, 1864, 2, 264.
17. Dybovsky, J.; Landrin, E. C.R. Acad Sci. (Paris), 1901, 133, 748.
18. Landrin, A. Bull. Sci. Pharmacol., 1905, 11, 319.
19. Taylor, W.I. JACS, 1957, 79, 3298.
20. Buchi, G.; Coffen, D.L.; Kocsis, K.; Sonnet, P.E.; Ziegler, F.E. JACS, 1966, 88, 3099.
21. Popik, P.; Skolnick, P. In The Alkaloids, G.A. Cordell, Ed.; Academic Press: San Diego, 1999, pp. 197-231.
22. Popik, P.; Glick, S.D. Drugs of the Future, 1996, 21, 1109.
23. Cappendijk, S.L.T.; Dzoljic, M.R. Eur. J Pharmacol., 1994, 241, 261.
24. Pearl, S. M.; Johnson, D.W.; Glick, S.D. Psychopharmacology, 1995, 121, 470.
25. Sershen, H.; Hashim, A.; Lajtha, A. Pharmacol. Biochem. Behav., 1996, 53, 863.
26. Rezvani, A.H., Overstreet, D.H.; Leef, Y.W. Pharmacol. Biochem. Behav., 1995, 52, 615.
27. Popik, P.; Layer R.T.; Skolnick P. Psychopharmacol., 1994, 114, 672.
28. Sershen, H.; Hashim, A.; Lajtha, A. Pharmacol. Biochem. Behav., 1996, 53, 863.
29. Sershen, H.; Hashim, A.; Lajtha, A. Brain Res. Bull., 1997, 42, 161.
30. Pearl, S.M.; Herrick-Davis, K.; Teitler, M.; Glick, S.D. Brain Res. 1995, 675, 342.
31. Mash, D.C.; Staley, J.K.; Pablo, J.P.; Holohean, A.M.; Hackman, J.C.; Davidoff, R. Neurosci. Lett., 1995, 192, 53.
32. Mash, D.C.; Staley, J.K.; Baumann, M.H.; Rothman, R.B.; Hearn, W. L. Life Sci., 1995, 57, PL45.
33. Sweetnam, P.M.; Lancaster, J.; Snowman, A.; Collins, J.; Perschke, S.; Bauer, C.; Ferkany, J. Psychopharmaco1., 1995, 118, 369.
34. Deecher, D.C.; Teitler, M.; Soderlund, D.M.; Bornmann, W.G.; Kuehne, M.E.; Glick, S.D. Brain Res., 1992, 571, 242.
35. Mach, R.H.; Smith, C.R.; Childers, S.R. Life Sci., 1995, 57, PL57.
36. Badio, B.; Padgett, W.L.; Daly, JW. Mol. Pharmacol., 1997, 51, 1.
37. Popik, P.; Layer, R.T.; Fossum, L.; Benveniste, M.; Getter-Douglas, B.; Witkin, J.M.; Skolnick, P. J. Pharmacol. Exp. Therap., 1995, 275, 753.
38. Trujillo, K.A.; Akil, H. Drug and Alcohol Dependence, 1995, 38, 139.
39. Benwell, M.E.M.; Holtom, P.E.; Moran, R.J.; Balfour, D.J.K. Brit. J. Pharmacol., 1996, 117, 743.
40. Iravani, M.M.; Kruk, Z.L. J. Neurochem., 1996, 66, 1076
41. Cheramy, A.; Godeheu, G.; Lhirondel, M.; Glowinski, J. J. Pharmacol. Exp. Therap., 1996, 276, 616.
42. Glick, S.D.; Maisonneuve, I.M. Ann. N. Y. Acad. Sci., 1998, 844, 214.
43. Alper, K.R.; Lotsof, H.S.; Frenken, G.M.N.; Luciano, D.J.; Bastiaans, J. Am. J. Addict., 1999, 8, 234.
44. Popik, P.; Layer, R.T.; Skolnick, P. Pharmacol. Rev., 1995, 47, 235.
45. Schneider, J.A.; McArthur, M. Experentia, 1956, 12, 323.
46. Syllabus, 1st International Conference on Ibogaine, New York, Nov. 5-6, 1999, pp 199-200.
47. O'Hearn, E.; Molliver, M.E. J. Neurosci., 1997, 17, 8828.
48. Mash, D.C.; Kovera, C.A.; Buck, B.E.; Norenberg, M.D.; Shapshak, P.; Hearn, W.L.; Sanchez-Ramos, J. Ann. N.Y. Acad. Sci., 1998, 844, 274.
49. Glick, S.D.; Maisonneuve, I.M.; Kitchen, B.A.; Fleck, M.W. Eur. J. Pharmacol., 2002, 438, 99.
50. Flores, C.M.; Rogers, S.W.; Pabreza, L.A.; Wolfe, B.B.; Kellar, K.J. Mol. Pharmacol., 1992, 41, 31.
51. Borne, R.F. Drug Topics, 1994, 138, 108.
52. Katzung, B.G.; Julius, D.J. In Basic & Clinical Pharmacology, B.G. Katzung, Ed.; Lange/McGraw-Hill: New York, 2001; 8th ed. pp. 265-291.
53. Glennon, R.A.; Dukat, M.; Westkaemper, R.B. In Psychopharmacology - The Fourth Generation of Progress, F.E. Bloom; D.J. Kupfer, Ed. http://www.acnp.org/g4/4thgen.php 2000.
54. Wei, D.; Maisonneuve, I.M.; Kuehne, M.E.; Glick, S.D. Brain Res., 1998, 800, 260.
55. Hartman, D.S. Civelli, O. Prog. in Drug Res., 1997, 48, 173.
56. Booth, R.G.; Baldessarini, R.J. Eur. J Pharmacol., 1990, 185, 217.
57. Booth, R.G.; Owens, C.E.; Brown, R.L. Brain Res., 1999, 837, 95.
58. Choksi, N.Y.: Nix, W.B.; Wyrick, S.D.; Booth, R.G. Brain Res., 2000, 852, 151.
59. Johnson, E.A.; Tsai, C.E.; Shahan, Y.H. J. Pharmacol. Exp. Ther., 1993, 266, 133.
60. Booth, R.G.; Baldessarini, R.J. Brain Res., 1991, 557, 349.
61. Dall'Olio, R.; Rimondini, R.; Gandolfi, O. Psychopharmacology, 1996, 123, 187.
62. Kulkarni, S.K.; Ninan, I. Fund. Clin. Pharmacol., 2000, 14, 529.
63. Mill, J.S.; Caspi, A.; McClay, J.; Sugden, K.; Purcell, S.; Asherson, P.; Craig, I.; McGuffin, P.; Braithwaite, A.; Poulton, R.; Moffitt, T.E. Mol Psychiatry, 2002, 7, 383.
64. Li, T.; Zhu, Z.H.; Liu, X.; Hu, X.; Zhao, J.; Sham, P.C.; Collier, D.A. Am. J Med Gen., 2000, 96, 616.
65. Li, T.; Xu, K.; Deng, H.; Cai, G.; Liu, J.; Liu, X.; Wang, R.; Xiang, X.; Zhao, J.; Murray, R.M.; Sham, P.C.; Collier, D.A. Mol Psychiatry, 1997, 2, 413.
66. Cooper, J.R.; Bloom, F.E.; Roth, R.H. The Biochemical Basis of Neuropharmacology, 7th ed., Oxford: New York, 1996.
67. Gonzales-Alvear, G.M.; Werling, L.L. J. Pharmacol. Exp. Ther., 1994, 271, 212.
68. Bowen, W.D.; Vilner, B.J.; Williams, W.; Bertha, C.M.; Kuehne, M.E.; Jacobson, A.E. Eur. J Pharmacol., 1995, 279, R1.
69. Madsen, U. In A Textbook of Drug Design and Development, P. Krogsgaard-Larsen, T. Liljefors, U. Madsen, Ed.; Harwood: Amsterdam, 1996; 2nd ed. pp. 235-253.
70. Mash, D.C.; Staley, J.K.; Pablo, J.P.; Holohean, A.M.; Hackman J.C.; Davidoff, R.A. Neurosci. Lett., 1995, 192, 53.
71. Gutstein, H.B.; Akil, H. In Goodman and Gilman's the Pharmacological Basis of' Therapeutics, J.G. Hardman; L.E. Limbird; A.G. Gilman, Ed.; McGraw-Hill: New York, 2001; 10th ed. pp. 569-619.
72. Mulder, A.H.; Wardeh, G.; Hogenboom, F.; Frankhuyzen, A.L. Nature, 1984, 308, 278.
73. Jackisch, R.; Holtz, H.; Hertting, G. Naunyn-Schmiedberg's Arch. Pharmacol., 1993, 348, 234.
74. Sershen, H.; Hashim, A.; Lajtha, A. Brain Res. Bull., 1995, 36, 587.
75. Graybiel, A.M.; Moratalla, R.; Robertson, H.A. Proc. Natl. Acad. Sci. U.S.A., 1990, 87, 6912.
76. Moratalla, R.; Robertson, H.A.; Graybiel, A.M. J. Neurosci., 1992, 12, 2609.
77. Young, S.T.; Porrino, L.J.; Iadarola, M.J. Proc. Natl. Acad. Sci. U.S.A., 1991, 88, 1291.
78. Herrera, D.G.; Robertson, H.A. Pro. Neurobiol., 1996, 50, 83.
79. Abraham, W.C.; Mason, S.E.; Demmer, J.; Williams, J.W.; Richardson, C.L.; Tate, W.P.; Lawlor, P.A.; Dragunow, M. Neuroscience, 1993, 56, 717.
80. Worley, P..F.; Bhat, R.V.; Baraban, J.M.; Erickson, C.A.; McNaughton, B.C.; Barnes, A. J. Neurosci., 1993, 231, 4776.
81. Mello, C.V.; Vicario, D.S.; Clayton, D.F. Proc. Natl. Acad. Sci. US.A., 1992, 89, 6818.
82. Ali, S.F.; Thiriet, N.; Zwiller, J. Mol. Brain Res., 1999, 74, 237.
83. Daoust, M.; Legrand, E.; Gewiss, M.; Heidbreder, C.; DeWitte, P.; Tran, G.; Durbin, P. Pharmacol. Biochem. Behav., 1992, 41, 669.
84. Madamba, S.G.; Schweitzer, P.; Zieglgansberger, W.; Siggins, G.R. Alcohol. Clin. Esp. Res., 1996, 20, 618.
85. Zeise, M.L.; Kasparov, S.; Capogna, M.; Zieglgansberger, W. Eur. J. Pharmacol., 1993, 231, 47.
86. Littleton, J. Addiction, 1995, 90, 1179.
87. Berton, F.; Francesconi, W.G.; Madamba, S.G.; Zieglgansberger, W.; Siggins, G.R. Alcohol Clin. Exp. Res., 1998, 22, 183-91.
88. Spanagel, R.; Zieglgansberger, W. Trends. Pharmacol. Sci., 1997, 18, 54.
89. Allgaier, C.; Franke, H.; Sobottka, H.; Schiebler, P. Arch. Pharmacol., 2000, 362, 440.
90. Wu, J-Y.; Jin, H.; Scholss, J.V.; Faiman, M.D.; Ningaraj, N.S.; Foss, T.; Chen, W.-J. Biomed. Sci., 2001, 8, 96.
91. Sass, H.; Sokya, M.; Mann, K.; Zieglgansberger, W. Arch. Gen. Psychiatry, 1996, 53, 673.
92. Whitworth, A.B.; Fischer, F.; Lesch, O.M.; Nimmerrichter, A.; Oberbauer, H.; Platz, T.; Potgieter, A.; Walter, H.; Fleishhacker, W.W. Lancet, 1996, 347, 1438.
93. Rammes, G.; Mahal, B.; Putzke, J.; Parsons, C.; Spielmanns, P.; Pestel, E.; Spranagel, R.; Zieglgansberger, W.; Schadrack, J. Neuropharmacol., 2001, 40, 749.
94. Schulman, A. World Patent WO 01/52851 A1, 2001.
95. Popik, P., Skolnick, P. Pharmacol. Biochem. Behav., 1996, 53, 791.
96. Belozertseva, I., Bespalov, A.Y. Naunyn Schmiedebergs Arch Pharmacol., 1998, 358, 270.
97. Popik, P.; Danysz, W. J. Pharmacol. Exp. Ther., 1997, 280, 854.
98. Semenova, S.G.; Danysz, W.; Bespalov, A.Y. Eur. J. Pharmacol., 1999, 378, 1.
99. Spanagel, R.; Zieglgänsberger, W. Trends Pharmacol. Sci., 1997, 18, 54.
100. Hölter, S.M.; Danysz, W.; Spanagel, R. Eur. J. Pharmacol., 1996, 314, R1.
101. www.meniantine.com
102. Emilien, G., Durlach, C., Aveaux, D., Maloteaux, J.-M. Exp. Opinion Ther. Pat., 2001, 11, 1713.
103. Pilla, M.; Perachon, S.; Sautel, F.; Garrido, F.; Mann, A.; Wermuth, C.G.; Schwartz, J-C.; Everitt, B.J.; Sokoloff, P. Nature (London), 1999, 400, 371.
104. Wood, M.D.; Boyfield, I.; Nash, D.J.; Jewitt, F.R.; Avenell, K.Y.; Riley, G.J. Eur. J. Pharmacol., 2000, 407, 47.
105. Rothman, R.B.; Mele, A.; Reid, A.A.; Akunne, H.C.; Grieg, N.; Thurkauf A.; deCosta, B.R.; Rice, K.C.; Pert, A. Pharmacol. Biochem. Behav., 1991, 40, 387.
106. Glowa, J.R.; Wojnicki, F.H.E.; Matecka, D.; Rice, K.C,; Rothman, R.B. Exp. Clin. Psychopharmacol., 1995, 3, 232.
107. Tella, S.R. Pharmacol. Biochem. Behav., 1995, 51, 687.
108. Lewis, D.B.; Matecka, D.; Zhang, Y.; Hsin, L-W.; Dersch, C.M.; Stafford, D.; Glowa, J.R.; Rothman, R.B.; Rice, K.C. J. Med. Chem., 1999, 42, 5029.
109. Baumann, M. H.; Ayestas, M.A.; Sharpe, L.G.; Lewis, D.B. Rice, K.C.; Rothman, R.B. J. Pharmacol. Exp. Ther., 2001, 301, 1190.
110. Wong, D.F.; Cantilena, L.; Elkashef, A.; Yokoi, F.; Dogan, S.; Stephane, M.; Gjedde, A.; Rothman, R.B.; Mojsiak, J.; Vocci, F. Soc. Neurosci. Abstr., 1999, 29, 242.
111. Sögaard, U.; Michalow, J.; Butler, B.; Lund Laursen, A.; Ingersen, S.H.; Skrumsager, B.K.; Rafaelsen, O.J. Int. Clin. Psychopharmacol., 1990, 5, 237.
112. Preti, A. Curr Opinion Invest Drugs, 2000, 1, 241.
113. Gourlay, S.G.; Benowitz, N.L. Drugs, 1995, 50, 197.
114. Myles, J.S. J. Psychopharmacol., 1996, 10(Suppl. 3), 49.
115. Lin, S-K.; Strang, J.; Su, L-W.; Tsai, C-J.; Hu, W-H. Drug Alcohol Dep., 1997, 48, 127.
116. Proksch, J.W.; Gentry, W.B.; Owens, S.M. J. Pharmacol. Exp. Ther., 2000, 292, 831.
117. Carrera, M.R.A.; Ashley, J.A.; Zhou, B.; Wirsching, P.; Koob, G.F.; Janda, K.D. Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 6202.
118. Janda, K.D. Book of Abstracts, 218th ACS National Meeting, New Orleans, Aug. 22-26, 1999, ORGN-261.
119. Borman, S. Chem. Eng. News, 1999, 77(38), 47.
120. http://us.gsk.com/products/assets/us_zyban.pdf
121. Jorenby, D.E.; Leischow, S.J,; Nides, M.A.; Rennard, S.I.; Johnston, J.A.; Hughes, A.R.; Smith, S.S.; Muramoto, M.L.; Daughton, D.M.; Doan, K.; Fiore, M.C., Baker, T.B. N. Engl. J. Med, 1999, 340, 685.
122. Hurt R.D.; Sachs, D.P.; Glover, E.D.; Offord, K.P.; Johnston, J.A,; Dale, L.C.; Khayrallah, M.A.; Schroeder, D.R,; Glover, P.N.; Sullivan, C.R.; Croghan, I.T.; Sullivan, P.M. N. Engl. J. Med., 1997, 337, 1195.
123. Jorenby, D.E.; Hatsukami, D.K.; Smith, S.S.; Fiore, M.C. Allen, S.; Jensen, J.; Baker, T.B. Psychopharmacology (Berlin), 1996, 128, 130.
124. Nides, M.; Rand, C.; Dolce, J.; Murray, R., O'Hara, P; Voelker, H.; Connett, J. Health Psychol., 1994, 13, 354.
125. http://www.drugtext.org/books/methandbook/default.htm